K

Karyopharm Therapeutics
D

KPTI

7.45000
USD
0.70
(10.37%)
مغلق
حجم التداول
1,527
الربح لكل سهم
-13
العائد الربحي
-
P/E
-1
حجم السوق
63,847,819
أصول ذات صلة
BMY
BMY
1.000
(2.02%)
50.560 USD
B
BPMC
5.400
(5.44%)
104.720 USD
GILD
GILD
0.420
(0.41%)
103.660 USD
INCY
INCY
0.500
(0.81%)
62.500 USD
MRK
MRK
-0.090
(-0.11%)
83.160 USD
NVS
NVS
3.000
(2.69%)
114.320 USD
PFE
PFE
0.065
(0.27%)
24.185 USD
Z
ZYME
0.090
(0.70%)
12.950 USD
المزيد
الأخبار المقالات

العنوان: Karyopharm Therapeutics Inc.

القطاع: Healthcare
الصناعة: Biotechnology
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuselarge B-cell lymphoma. The company derives its revenue from United States.